© 2004 by European Society of Cardiology
Copyright © 2004, European Society of Cardiology
The endothelin system in pulmonary arterial hypertension
Institute of Cardiology, University of Bologna, via Massarent 9, 40138-Bologna, Italy
* Corresponding author. Tel.: +39-051-349858; fax: +39-051-344859. n.galie{at}bo.nettuno.it
Endothelin-1 (ET-1), a peptide produced primarily by vascular endothelial cells, was discovered in 1980 and it was characterized as a powerful vasoconstrictor and mitogen for smooth muscle. ET-1 binds to two types of receptors, ETA and ETB: ETA-receptors are found in smooth muscle cells, whereas ETB-receptors are localized on both endothelial cells and in smooth muscle cells. Activation of ETA- and ETB-receptors on smooth muscle cells mediates the vasoconstrictive and mitogenic effects of ET-1. Stimulation of endothelial ETB-receptors promotes ET-1 clearance and activation of NO and prostacyclin release. Pulmonary arterial hypertension (PAH) is a severe condition characterized by a progressive increase in pulmonary vascular resistance leading to right ventricular failure and death. An activation of the ET-1 system has been demonstrated in both plasma and lung tissues of PAH patients as well as in animal models of PAH. The most efficient way to antagonize the ET-1 system is the use of ET-1 receptor antagonists that can block either ETA- or ETA- and ETB-receptors. These drugs are effective in animal models of PAH and have been tested in multiple clinical trials in patients with PAH. Bosentan, an orally active, dual ET-1 receptor antagonist has been shown to improve symptoms, exercise capacity, hemodynamics, echocardiographic parameters and the outcome of patients with severe PAH, and it has been approved for clinical use in many countries. The selective ETA-receptor antagonist sitaxentan has improved exercise capacity and hemodynamics of PAH patients in two preliminary studies. The main side effect of ET-1 antagonists is the increase of liver enzymes likely due to an accumulation of bile salts cytotoxic to hepatocytes. Additional trials with these drugs are currently ongoing. In conclusion, the hypothesis that the ET-1 system over-activation can be successfully antagonised in patients with PAH has been clearly demonstrated.
KEYWORDS Pulmonary circulation; Endothelins; Endothelial function; Endothelial receptors; Vasoconstriction/dilation
Time for primary review 28 days
CiteULike 
Connotea 
Del.icio.us What's this?
This article has been cited by other articles:
|
|
 |
|
  Authors/Task Force Members, N. Galie, M. M. Hoeper, M. Humbert, A. Torbicki, J.-L. Vachiery, J. A. Barbera, M. Beghetti, P. Corris, S. Gaine, et al. Guidelines for the diagnosis and treatment of pulmonary hypertension: The Task Force for the Diagnosis and Treatment of Pulmonary Hypertension of the European Society of Cardiology (ESC) and the European Respiratory Society (ERS), endorsed by the International Society of Heart and Lung Transplantation (ISHLT) Eur. Heart J., October 2, 2009; 30(20): 2493 - 2537. [Full Text] [PDF]
|
|
|
|
 |
|
 X. Li, X.-L. Wei, L.-L. Meng, M.-G. Chi, J.-Q. Yan, X.-Y. Ma, Y.-S. Jia, L. Liang, H.-T. Yan, and J.-Q. Zheng Involvement of Tissue Transglutaminase in Endothelin 1-Induced Hypertrophy in Cultured Neonatal Rat Cardiomyocytes Hypertension, October 1, 2009; 54(4): 839 - 844. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 O. Mercier, E. Sage, M. de Perrot, L. Tu, E. Marcos, B. Decante, B. Baudet, P. Herve, P. Dartevelle, S. Eddahibi, et al. Regression of flow-induced pulmonary arterial vasculopathy after flow correction in piglets. J. Thorac. Cardiovasc. Surg., June 1, 2009; 137(6): 1538 - 1546. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. G.J. Duffels, M. Hardziyenka, S. Surie, R. H.A.C.M de Bruin-Bon, E. S. Hoendermis, A. P.J. van Dijk, B. J. Bouma, H. L. Tan, R. M.F. Berger, P. Bresser, et al. Duration of right ventricular contraction predicts the efficacy of bosentan treatment in patients with pulmonary hypertension Eur J Echocardiogr, May 1, 2009; 10(3): 433 - 438. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. Yndestad, K.-O. Larsen, E. Oie, T. Ueland, C. Smith, B. Halvorsen, I. Sjaastad, O. H. Skjonsberg, T. M. Pedersen, O.-G. Anfinsen, et al. Elevated levels of activin A in clinical and experimental pulmonary hypertension J Appl Physiol, April 1, 2009; 106(4): 1356 - 1364. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 G. CELLA, F. VIANELLO, F. COZZI, H. MAROTTA, F. TONA, G. SAGGIORATO, O. IQBAL, and J. FAREED Effect of Bosentan on Plasma Markers of Endothelial Cell Activity in Patients with Secondary Pulmonary Hypertension Related to Connective Tissue Diseases J Rheumatol, April 1, 2009; 36(4): 760 - 767. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. Zhang, Y. Ling, L. Tang, B. Luo, D. M. Pollock, and M. B. Fallon Attenuation of experimental hepatopulmonary syndrome in endothelin B receptor-deficient rats Am J Physiol Gastrointest Liver Physiol, April 1, 2009; 296(4): G704 - G708. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. P. Comellas, A. Briva, L. A. Dada, M. L. Butti, H. E. Trejo, C. Yshii, Z. S. Azzam, J. Litvan, J. Chen, E. Lecuona, et al. Endothelin-1 Impairs Alveolar Epithelial Function via Endothelial ETB Receptor Am. J. Respir. Crit. Care Med., January 15, 2009; 179(2): 113 - 122. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 N. Galiè and A. Manes CHAPTER 24 Pulmonary Hypertension ESC Textbook of Cardiovascular Medicine, January 1, 2009; 2(1): med-9780199566990-chapter - med-9780199566990-chapter. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 W. B. Mathews, N. Murugesan, J. Xia, U. Scheffel, J. Hilton, H. T. Ravert, R. F. Dannals, and Z. Szabo Synthesis and In Vivo Evaluation of Novel PET Radioligands for Imaging the Endothelin-A Receptor J. Nucl. Med., September 1, 2008; 49(9): 1529 - 1536. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 T. L. Thai and W. J. Arendshorst ADP-ribosyl cyclase and ryanodine receptors mediate endothelin ETA and ETB receptor-induced renal vasoconstriction in vivo Am J Physiol Renal Physiol, August 1, 2008; 295(2): F360 - F368. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 F Iannone, M T Riccardi, S Guiducci, R Bizzoca, M Cinelli, M Matucci-Cerinic, and G Lapadula Bosentan regulates the expression of adhesion molecules on circulating T cells and serum soluble adhesion molecules in systemic sclerosis-associated pulmonary arterial hypertension Ann Rheum Dis, August 1, 2008; 67(8): 1121 - 1126. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 N. Galie, H. Olschewski, R. J. Oudiz, F. Torres, A. Frost, H. A. Ghofrani, D. B. Badesch, M. D. McGoon, V. V. McLaughlin, E. B. Roecker, et al. Ambrisentan for the Treatment of Pulmonary Arterial Hypertension: Results of the Ambrisentan in Pulmonary Arterial Hypertension, Randomized, Double-Blind, Placebo-Controlled, Multicenter, Efficacy (ARIES) Study 1 and 2 Circulation, June 10, 2008; 117(23): 3010 - 3019. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. Behr and J. H. Ryu Pulmonary hypertension in interstitial lung disease Eur. Respir. J., June 1, 2008; 31(6): 1357 - 1367. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 H. H. Leuchte, T. Meis, M. El-Nounou, J. Michalek, and J. Behr Inhalation of endothelin receptor blockers in pulmonary hypertension Am J Physiol Lung Cell Mol Physiol, April 1, 2008; 294(4): L772 - L777. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. H. Ryu, M. J. Krowka, K. L. Swanson, P. A. Pellikka, and M. D. McGoon Pulmonary Hypertension in Patients With Interstitial Lung Diseases Mayo Clin. Proc., March 1, 2007; 82(3): 342 - 350. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 L. Calderon-Garciduenas, M. Franco-Lira, R. Torres-Jardon, C. Henriquez-Roldan, G. Barragan-Mejia, G. Valencia-Salazar, A. Gonzalez-Maciel, R. Reynoso-Robles, R. Villarreal-Calderon, and W. Reed Pediatric Respiratory and Systemic Effects of Chronic Air Pollution Exposure: Nose, Lung, Heart, and Brain Pathology Toxicol Pathol, January 1, 2007; 35(1): 154 - 162. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 B. Houweling, D. Merkus, O. Sorop, F. Boomsma, and D. J. Duncker Role of endothelin receptor activation in secondary pulmonary hypertension in awake swine after myocardial infarction J. Physiol., July 15, 2006; 574(2): 615 - 626. [Abstract] [Full Text] [PDF]
|
|